These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33755732)

  • 21. Risk of second primary breast cancer after radioactive iodine treatment in thyroid cancer: a systematic review and meta-analysis.
    Zhang Y; Liang J; Li H; Cong H; Lin Y
    Nucl Med Commun; 2016 Feb; 37(2):110-5. PubMed ID: 26513055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of Breast Cancer in Patients with Thyroid Cancer Receiving or Not Receiving 131I Treatment: A Nationwide Population-Based Cohort Study.
    Lin CY; Lin CL; Huang WS; Kao CH
    J Nucl Med; 2016 May; 57(5):685-90. PubMed ID: 26719377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feasibility Study Shows Multicenter, Observational Case-Control Study Is Practicable to Determine Risk of Secondary Breast Cancer in Females With Differentiated Thyroid Carcinoma Given Radioiodine Therapy in Their Childhood or Adolescence; Findings Also Suggest Possible Fertility Impairment in Such Patients.
    Drozd V; Schneider R; Platonova T; Panasiuk G; Leonova T; Oculevich N; Shimanskaja I; Vershenya I; Dedovich T; Mitjukova T; Grelle I; Biko J; Reiners C
    Front Endocrinol (Lausanne); 2020; 11():567385. PubMed ID: 33193085
    [No Abstract]   [Full Text] [Related]  

  • 24. Second primary malignancies in thyroid cancer patients.
    Rubino C; de Vathaire F; Dottorini ME; Hall P; Schvartz C; Couette JE; Dondon MG; Abbas MT; Langlois C; Schlumberger M
    Br J Cancer; 2003 Nov; 89(9):1638-44. PubMed ID: 14583762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
    Marti JL; Jain KS; Morris LG
    Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
    Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
    Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer.
    Slonimsky E; Tulchinsky M
    Curr Pharm Des; 2020; 26(31):3812-3827. PubMed ID: 32503402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer Risk After Radioactive Iodine Treatment for Hyperthyroidism: A Systematic Review and Meta-analysis.
    Shim SR; Kitahara CM; Cha ES; Kim SJ; Bang YJ; Lee WJ
    JAMA Netw Open; 2021 Sep; 4(9):e2125072. PubMed ID: 34533571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Childhood thyroid cancers and radioactive iodine therapy: necessity of precautious radiation health risk management.
    Kumagai A; Reiners C; Drozd V; Yamashita S
    Endocr J; 2007 Dec; 54(6):839-47. PubMed ID: 17938505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shortened telomere length in peripheral blood leukocytes is associated with cumulative radioactive iodine doses in patients with differentiated thyroid carcinoma.
    Choi H; Cho SW; Kim HH; Yi KH; Park DJ; Park YJ
    Cancer; 2024 Jun; 130(12):2215-2223. PubMed ID: 38376914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: An institutional experience and review of the literature.
    Gow KW; Lensing S; Hill DA; Krasin MJ; McCarville MB; Rai SN; Zacher M; Spunt SL; Strickland DK; Hudson MM
    J Pediatr Surg; 2003 Nov; 38(11):1574-80. PubMed ID: 14614703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients.
    Mei X; Yao X; Feng F; Cheng W; Wang H
    BMC Cancer; 2021 May; 21(1):543. PubMed ID: 33980182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic Immune Function Changes Before and After the First Radioactive Iodine Therapy After Total Resection of Differentiated Thyroid Carcinoma.
    Shi ZY; Zhang SX; Fan D; Li CH; Cheng ZH; Xue Y; Wu LX; Lu KY; Yang SY; Cheng Y; Wu ZF; Gao C; Li XF; Liu HY; Li SJ
    Front Immunol; 2022; 13():901263. PubMed ID: 35844520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of Subsequent Primary Cancers in Thyroid Cancer Survivors according to the Dose of Levothyroxine: A Nationwide Cohort Study.
    Kim MS; Lee JW; Hyun MK; Song YS
    Endocrinol Metab (Seoul); 2024 Apr; 39(2):288-299. PubMed ID: 38437824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.
    Khang AR; Cho SW; Choi HS; Ahn HY; Yoo WS; Kim KW; Kang KW; Yi KH; Park DJ; Lee DS; Chung JK; Cho BY; Park YJ
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):117-23. PubMed ID: 25115234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer.
    Kim KJ; Kim KJ; Choi J; Kim NH; Kim SG
    J Natl Cancer Inst; 2023 Jun; 115(6):695-702. PubMed ID: 36821433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
    Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
    Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thyroid adenomas after solid cancer in childhood.
    Haddy N; El-Fayech C; Guibout C; Adjadj E; Thomas-Teinturier C; Oberlin O; Veres C; Pacquement H; Jackson A; Munzer M; N'Guyen TD; Bondiau PY; Berchery D; Laprie A; Bridier A; Lefkopoulos D; Schlumberger M; Rubino C; Diallo I; de Vathaire F
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):e209-15. PubMed ID: 22672756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgical Risk Prediction for Nasolacrimal Duct Obstruction in Radioactive Iodine-Treated Thyroid Cancer: A Nationwide Cohort Study.
    Lee JY; Woo KI
    Thyroid; 2022 May; 32(5):544-551. PubMed ID: 34894720
    [No Abstract]   [Full Text] [Related]  

  • 40. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment.
    Fallahi B; Adabi K; Majidi M; Fard-Esfahani A; Heshmat R; Larijani B; Haghpanah V
    Clin Nucl Med; 2011 Apr; 36(4):277-82. PubMed ID: 21368600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.